Second-line dovitinib in metastatic endometrial cancer

Research output: Contribution to journalArticle

1 Citation (Scopus)
Original languageEnglish (US)
Pages (from-to)604-606
Number of pages3
JournalThe Lancet Oncology
Volume16
Issue number6
DOIs
StatePublished - Jun 1 2015

Fingerprint

Antineoplastic Combined Chemotherapy Protocols
Receptor, Fibroblast Growth Factor, Type 2
Benzimidazoles
Quinolones
Endometrial Neoplasms
4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one

ASJC Scopus subject areas

  • Oncology

Cite this

Second-line dovitinib in metastatic endometrial cancer. / Block, Matthew S; Dowdy, Sean Christopher.

In: The Lancet Oncology, Vol. 16, No. 6, 01.06.2015, p. 604-606.

Research output: Contribution to journalArticle

@article{2e7e4608a06d4cea914d7f637fb78979,
title = "Second-line dovitinib in metastatic endometrial cancer",
author = "Block, {Matthew S} and Dowdy, {Sean Christopher}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/S1470-2045(15)70190-7",
language = "English (US)",
volume = "16",
pages = "604--606",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "6",

}

TY - JOUR

T1 - Second-line dovitinib in metastatic endometrial cancer

AU - Block, Matthew S

AU - Dowdy, Sean Christopher

PY - 2015/6/1

Y1 - 2015/6/1

UR - http://www.scopus.com/inward/record.url?scp=84930277749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930277749&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(15)70190-7

DO - 10.1016/S1470-2045(15)70190-7

M3 - Article

C2 - 25981815

AN - SCOPUS:84930277749

VL - 16

SP - 604

EP - 606

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 6

ER -